Navigation Links
Cholesterol Drug Fails to Slow Progression of Coronary Disease,,Cleveland Clinic Study Reports

NEW ORLEANS, March 26, 2007 /PRNewswire/ -- Cleveland Clinic researchers today report that the drug torcetrapib, despite raising high density lipoprotein cholesterol (HDL) or the "good" cholesterol by more than 60%, did not slow the progression of plaque buildup in the coronary arteries as measured using an ultrasound probe.

Steven Nissen, M.D., Chairman of Cardiovascular Medicine at Cleveland Clinic and lead investigator of this clinical trial, will present the study on Monday, March 26 at 8:30 a.m. at the of Cardiology's (ACC) 56th Annual Scientific Session. Dr. Nissen is also President of the ACC. The study will be simultaneously published in the New England Journal of Medicine.

All development of this drug was terminated on Dec. 2, 2006 after the safety board monitoring a separate large clinical outcomes trial reported that torcetrapib increased the risk of death and other adverse cardiovascular outcomes.

"We found that the torcetrabip/atorvastatin combination markedly increased good cholesterol levels and lowered bad cholesterol in patients. Unfortunately this drug also substantially raised blood pressure and failed to slow the buildup of plaque," Dr. Nissen said. "It is yet to be determined of this failure represents a problem unique to torcetrapib or predicts a lack of efficacy for the entire class of similar drugs. These findings further demonstrate the great difficulty in developing therapies to disrupt the atherosclerotic disease process."

The development of drugs to raise HDL has been a key research priority because, despite lowering LDL (low-density lipoprotein, or "bad") cholesterol with statin drugs, many patients continue to experience heart attacks, stroke or sudden cardiac death.

A total of 1,188 coronary artery disease patients were enrolled in the "Investigation of Lipid Level management using coronary UltraSound To assess Reduction of Atherosclerosis by CET
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Low-Density Cholesterol Subfractions: Not all LDL-C Particles are Created Equal
2. Lexicon Develops Antibodies That Lower Triglycerides and Cholesterol as Potential New Therapy for Heart Disease
3. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
4. KineMed Presents Data Measuring Changes in Reverse Cholesterol Transport for the First Time
5. CSL Therapy That Mimics “Good” Cholesterol May Reduce Plaque Volume in Coronary Arteries
6. CSL Therapy That Mimics Good Cholesterol May Reduce Plaque Volume in Coronary Arteries
7. Treating Heart Disease Risk Factors May Slow Alzheimers Disease Progression
8. Caelyx Delays Time to Disease Progression as Maintenance Therapy in Patients with Metastatic Breast Cancer
9. Merck at ASCO 2007: Encouraging Results in Progression-Free Survival in Patients With Aggressive Brain Tumors (glioblastoma) Using Cilengitide in Phase I/IIa Study
10. The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved Progression Free Survival When Given Before and After Surgery in Patients With Resectable Liver Metastases From Colorectal Cancer
11. Multiferon Shows Potent Activity in Preventing the Progression of Malignant Melanoma; Study to be Published
Post Your Comments:
(Date:12/17/2014)... ANGELES , Dec. 17, 2014  ImmunoCellular ... the US Patent and Trademark Office (USPTO) has ... ICT-107, a dendritic cell-based immunotherapeutic vaccine targeting six ... The claims of US Patent No. 8,871,211, which ... neural cancer by administering a dendritic cell composition ...
(Date:12/17/2014)... and RALEIGH, N.C. ... Marketing Communications, LLC (CTMC), and Integrated Clinical Trial ... recruitment and retention for clinical trials announce that ... Clinical Trial Marketing Services (i-CTMS). i-CTMS will provide ... services to pharmaceutical, biotechnology and medical device companies. ...
(Date:12/15/2014)... 2014 Research and Markets ( ... "MEMS Gyroscopes Analog Devices ADIS16136 Precision Angular ... their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... applications made a lot of progress in the ... are now accepted in high-reliability environments, and are ...
Breaking Medicine Technology:ImmunoCellular Therapeutics Announces Issuance of Key Patent For ICT-107 Cancer Vaccine 2Integrated Clinical Trial Services and Clinical Trial Marketing Communications Form Joint Venture 2Integrated Clinical Trial Services and Clinical Trial Marketing Communications Form Joint Venture 3MEMS Gyroscopes Analog Devices ADIS16136 Precision Angular Rate Sensor Reverse Costing Analysis 2
... BEIJING , July 7 ... the "Company") (NYSE: CCM ), operator of,the largest ... ,today announced that it has filed its annual report for ... 20-F with the U.S. Securities and Exchange,Commission on June ...
... , SAN FRANCISCO , July 7 ... (Nasdaq: NLTX ), a biopharmaceutical company focused on ... announced that it has completed the dosing of the ... II study of CD-NP in patients with acute decompensated ...
Cached Medicine Technology:Concord Medical Files 2009 Annual Report on Form 20-F 2Nile Therapeutics Completes Dosing of Phase II Study 2Nile Therapeutics Completes Dosing of Phase II Study 3
(Date:12/19/2014)... THURSDAY, Dec. 18, 2014 (HealthDay News) -- Prostaglandin analogue ... -- significantly reduce the risk of vision loss in ... British researchers led by David Garway-Heath, of the ... London, tracked outcomes for more than 500 people newly ... of the disease and one of the leading causes ...
(Date:12/17/2014)... Myo Nwe is the co-author of a new weight loss ... of the Ace Medical Weight Loss Center in Rock Hill, ... at the industry of weight loss, and how several fad ... in television shows, however, she says the topic of obesity ... for basic laughs, which she believes impacts whether Americans view ...
(Date:12/17/2014)... HeartMath® Inc., recognized as one of ... variability (HRV), heart coherence and the physiology of ... and algorithms to chipset manufacturers and consumer electronics ... to offer its HRV solutions, tap into its ... its normative HRV databases and algorithms for developing ...
(Date:12/17/2014)... 17, 2014 No matter how far ... to eradicate the head louse parasite—a common childhood malady ... Each year between six and twelve million individuals will ... lice removal treatment company comes to the rescue, providing ... friendly. With its track record of customer service, and ...
(Date:12/17/2014)... MONDAY, Dec. 15, 2014 (HealthDay News) -- As gas ... and deaths, a new study suggests. In times ... many of those riders are inexperienced, the researchers explained. ... in California, which has the highest number of motorcycle ... number of motorcyclist deaths. The analysis revealed a ...
Breaking Medicine News(10 mins):Health News:Study Supports Benefit of Widely Used Glaucoma Drug 2Health News:Obesity Should Not Be a Hollywood Punchline, Weight Loss Doc Says 2Health News:HeartMath® Inc.’s HRV Platform Solutions Available for Licensing 2Health News:HeartMath® Inc.’s HRV Platform Solutions Available for Licensing 3Health News:Lice Troopers Announces New Lice Treatment Clinic in Coral Gables to Service Key Biscayne, Coconut Grove, Kendall, Brickell & South Miami 2Health News:When Gas Prices Go Up, So Do Motorcycle Accidents, Study Finds 2
... first astronaut, involved in a 25 million dollar space ... on the growth of cancer cells in outer space, ... conduct research on cells, bacteria and the crystallisation of ... Molecule Medical Institute at the National University of Malaysia. ...
... College London have found that injections of stem cells ... of children with brittle bone disease , osteogenesis imperfecta ... foetuses by DNA testing or ultrasound, disrupts collagen production, ... the condition suffer fractures while in the womb, and ...
... on Wednesday proposed uprooting excess vineyards and launching an ... strategy aimed at soaking up glut and countering New ... that the European Union's annual wine budget of 1.3 ... "a very inefficient way" despite huge challenges facing the ...
... cat allergen is associated with greater bronchial responsiveness (BR) ... they are not specifically allergic to cats. This suggests ... allergic individuals, regardless of their specific allergies. ... lead author of the study. We presupposed that we ...
... Makes a Lot of Noise has had to turn it ... effect this week . But where there are 8,000,000 New ... of Environmental Protection has a phone line, 311, for quality-of-life ... callers say, is distracting, annoying, shrill, dull or rattling -- ...
... after tests on three dead swans in the northeast confirmed an ... fatal to humans. ,"France is not threatened by ... moment, a human contamination from the H5N1 virus," Health Minister Roselyne ... as the great flu epidemic that followed the war of 1914, ...
Cached Medicine News:Health News:EU Aims to Shake Up Wine Industry With Root-and-branch Reform 2Health News:Cat Exposure Increases Bronchial Responsiveness 2Health News:New York, the City That Roars 24/7, is Forced to Quiet Down 2Health News:New York, the City That Roars 24/7, is Forced to Quiet Down 3Health News:France Steps Up Vigilance After Bird Flu Outbreak 2
... The Thumper Board provides optimum head hyperextension, open ... intubation easier. Placed at strategic locations throughout ... CPR to be started immediately, and easy conversion ... patient application can be done in less than ...
The CryoSurgery console is the control center for CryoCath's surgical probe. It is a modular system made up of a console control unit and a tank dolly system. The system can be used as a unit or in s...
... CryoCath has developed a minimally ... reentrant tachycardia. It delivers a very ... site confirmation, pinpoint site precision, minimal ... thrombus and stenosis., ,Freezor is a ...
The Valve Mapper Steerocath-Dx has a unique "peanut" shaped tip. It is designed to conform to the anatomy during mapping procedures. Both 8F/8mm and 8F/6mm tips are available....
Medicine Products: